Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Virol Methods. 2021 Feb 27;292:114113. doi: 10.1016/j.jviromet.2021.114113

Table 2.

Comparing results of AmpFire (Test) and Roche LA-HPV (Reference) for 15 HR-HPV types from 149 specimens (n=2235).

HPV type P/P P/N N/P N/N Concordance (%) Kappa (95% CI) Prevalence Test Prevalence Reference
HPV16 42 6 4 97 139/149 (93.3) 0.84 (0.68–1.00) 32.2 30.9
HPV18 17 6 5 121 138/149 (92.6) 0.71 (0.55–0.87) 15.4 14.8
HPV31 9 20 1 119 128/149 (85.9) 0.40 (0.27–0.54) 19.5 6.7
HPV33 19 13 2 115 134/149 (89.9) 0.66 (0.50–0.81) 21.5 14.1
HPV35 23 11 3 112 135/149 (90.6) 0.71 (0.55–0.87) 22.8 17.4
HPV39 10 9 6 124 134/149 (89.9) 0.51 (0.35–0.67) 12.8 10.7
HPV45 12 7 1 129 141/149 (94.6) 0.72 (0.56–0.88) 12.8 8.7
HPV51 20 12 3 114 134/149 (89.9) 0.67 (0.51–0.82) 21.5 15.4
HPV52 29 12 11 97 126/149 (84.6) 0.61 (0.44–0.77) 27.5 26.8
HPV53 29 11 2 107 136/149 (91.3) 0.76 (0.60–0.92) 26.9 21.5
HPV56 13 11 1 124 137/149 (91.9) 0.64 (0.48–0.79) 15.4 9.4
HPV58 23 13 6 107 130/149 (87.2) 0.62 (0.46–0.79) 24.2 19.5
HPV59 16 5 2 126 142/149 (95.3) 0.79 (0.63–0.95) 14.1 12.1
HPV66 14 6 5 124 138/149 (92.6) 0.67 (0.51–0.84) 13.4 12.8
HPV68 12 25 9 103 115/149 (77.2) 0.28 (0.13–0.43) 24.8 14.1
15 HR-HPVs 288 167 61 1719 2007/2235 (89.8) 0.65 (0.61–0.69)

P; positive, N; negative, Data represented as the ratio of AmpFire/Roche LA-HPV results, Prevalence is shown as percentage.